Treatment of tumors
The invention provides for innovative improvements in tumor therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity.
1. A method of treating tumor diseases other than lung cancer comprising administering to a human patient in need thereof a recombinant, human, water-soluble, glycosylated with a sugar content greater than 10% by weight of total ACE2, dimeric angiotensin-converting-enzyme-2 (ACE2) polypeptide with ACE2 activity, wherein said recombinant, human, water-soluble, glycosylated with a sugar content greater than 10% by weight of total ACE2, dimeric ACE2 polypeptide comprises amino acids 18-740 of human wild type 805 amino acid ACE2, and wherein the tumor diseases are characterized by an increased angiotensin-II concentration in the tumor or in the tumor environment or in the tumor patient.
2. The method according to claim 1 , wherein the tumor disease is selected from tumor diseases of the reproductive tract selected from the group consisting of: ovarian cancer, testicular cancer, prostate cancer or breast cancer, tumor diseases of the digestive tract, stomach cancer, intestinal cancer, rectum carcinoma, pancreatic cancer, esophagus cancer and liver cancer, kidney cancer, melanomas and neuroblastomas.
3. The method according to claim 1 , wherein the recombinant, human, water-soluble, glycosylated with a sugar content greater than 10% by weight of total ACE2, dimeric ACE2 polypeptide is administered in combination with known therapy concepts selected from the group consisting of: radiotherapy, chemotherapy, hormone therapy, antibody therapy, a targeted therapy and surgical tumour removal, and wherein the polypeptide is used for the treatment of the effects, or side-effects, of the known therapy concepts.
4. The method according to claim 1 , wherein the tumor disease is tumor metastasis.
5. The method according to claim 1 , wherein the tumor disease is selected from the group consisting of: malignant effusions, edemas and increased vascular permeability associated with the tumor diseases.
6. The method according to claim 1 , wherein the recombinant, human, water-soluble, glycosylated with a sugar content greater than 10% by weight of total ACE2, dimeric ACE2 polypeptide is administered in a form selected from the group consisting of: a systemically applicable form, an intravenously applicable form, a nasal spray, and a liposomal form.
7. The method according to claim 1 , wherein the recombinant, human, water-soluble, glycosylated with a sugar content greater than 10% by weight of total ACE2, dimeric ACE2 polypeptide is administered in a form selected from the group consisting of: a locally applicable form, intratumorous form, subcutaneous form and intradermal form.
8. The method according to claim 1 , wherein the recombinant, human, water-soluble, glycosylated with a sugar content greater than 10% by weight of total ACE2, dimeric ACE2 polypeptide is used in combination with conventional tumor therapy, wherein the conventional tumor therapy is selected from the group consisting of: radiotherapy, chemotherapy, antibody therapy and surgical tumor removal.
9. The method according to claim 1 , wherein the tumor disease is characterized by a negative prognosis for the patient.